My first post in this thread was from two months ago (July 14th, 2017). I'm just re-posting but adjusting the timelines now that we are two months further along without any update from the company. Timelines are from the four most recent posted Zenith slide decks starting with the Annual Meeting in December 2016....focusing on the status of the single agent ZEN-3694 trial. The ZEN-3694/enzalutamide combo is still in dose escalation stage as of June 20 2016. Updated timelines appear like this.
Based on the info in the slides, here's where we stand now for the single agent ZEN-3694 trial:
- It has been 9 months since confirming the maximally tolerated dose (MTD) with every day dosing.
- Longest patient on drug should now be at around 14 months (assuming the patient is still alive).
- It has been 7 months since an intermittent dosing cohort was initiated. This may have just been a small cohort and it is unclear to me whether intermittent dosing was chosen as the recommended Phase 2 Dose
- Dose expansion cohort at recommended Phase 2 dose initiated about 3 months ago. As stated above, unclear if this dosing is every day or intermittent dosing.
- ClinicalTrials.gov was updated about a month ago and the trial now has a status of "This study is ongoing, but not recruiting participants."
